CY1105883T1 - Μεθοδος θepαπειας ή προληψης διαταραχων οπου μεσολαβει το ανοσοποιητικο και φαρμακευτικο παρασκευασμα για χρηση σε αυτη - Google Patents
Μεθοδος θepαπειας ή προληψης διαταραχων οπου μεσολαβει το ανοσοποιητικο και φαρμακευτικο παρασκευασμα για χρηση σε αυτηInfo
- Publication number
- CY1105883T1 CY1105883T1 CY20061101851T CY061101851T CY1105883T1 CY 1105883 T1 CY1105883 T1 CY 1105883T1 CY 20061101851 T CY20061101851 T CY 20061101851T CY 061101851 T CY061101851 T CY 061101851T CY 1105883 T1 CY1105883 T1 CY 1105883T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical preparation
- prevention
- treatment
- estrogenic component
- disorders involving
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 230000001076 estrogenic effect Effects 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Μία πλευρά της παρούσας εφεύρεσης αναφέρεται σε μέθοδο θεραπείας ή πρόληψης διαταραχής όπου μεσολαβεί το ανοσοποιητικό σε θηλαστικό, με την εν λόγω μέθοδο να περιλαμβάνει τη χορήγηση θεραπευτικώς αποτελεσματικής ποσότητας κάποιου οιστρογονικού συστατικού στο εν λόγω θηλαστικό, όπου το οιστρογονικό συστατικό επιλέγεται από την ομάδα που αποτελείται από: ουσίες αντιπροσωπευόμενες από τον ακόλουθο τύπο (Ι), στον οποίο τύπο R1, R2, R3, R4 ανεξαρτήτως είναι άτομο υδρογόνου, υδροξυλο ομάδα ή αλκοξυ ομάδα με 1-5 άτομα άνθρακα· έκαστο των R5, R6, R7 είναι υδροξυλο ομάδα· μέχρι και 3 των R1, R2, R3, R4 είναι άτομα υδρογόνου· πρόδρομες ενώσεις ικανές να απελευθερώσουν κάποια ουσία σύμφωνα με τον προαναφερθέντα τύπο όταν χρησιμοποιούνται στην παρούσα μέθοδο· και μείγματα μίας ή περισσοτέρων των προαναφερθεισών ουσιών και/ή προδρόμων ενώσεων. Μία άλλη πλευρά της εφεύρεσης αναφέρεται σε φαρμακευτικό παρασκεύασμα που περιλαμβάνει το προαναφερθέν οιστρογονικό συστατικό, κάποιο ανοσοθεραπευτικό μέσο και κάποιο φαρμακευτικά αποδεκτό έκδοχο.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077272 | 2002-06-11 | ||
| PCT/NL2003/000422 WO2003103684A1 (en) | 2002-06-11 | 2003-06-11 | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| EP03741634A EP1511496B1 (en) | 2002-06-11 | 2003-06-11 | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105883T1 true CY1105883T1 (el) | 2011-02-02 |
Family
ID=29724474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101851T CY1105883T1 (el) | 2002-06-11 | 2006-12-22 | Μεθοδος θepαπειας ή προληψης διαταραχων οπου μεσολαβει το ανοσοποιητικο και φαρμακευτικο παρασκευασμα για χρηση σε αυτη |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7923440B2 (el) |
| EP (1) | EP1511496B1 (el) |
| CN (1) | CN1691947B (el) |
| AT (1) | ATE340579T1 (el) |
| AU (1) | AU2003274946A1 (el) |
| CA (1) | CA2489271C (el) |
| CY (1) | CY1105883T1 (el) |
| DE (1) | DE60308679T2 (el) |
| DK (1) | DK1511496T3 (el) |
| ES (1) | ES2274252T3 (el) |
| PT (1) | PT1511496E (el) |
| SI (1) | SI1511496T1 (el) |
| WO (1) | WO2003103684A1 (el) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG195118A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
| WO2012164095A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| EP2653163A1 (en) * | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
| WO2015040051A1 (en) | 2013-09-18 | 2015-03-26 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
| US10894014B2 (en) | 2015-06-18 | 2021-01-19 | Estetra Sprl | Orodispersible tablet containing Estetrol |
| SI3310346T1 (sl) | 2015-06-18 | 2021-07-30 | Estetra Sprl | Orodisperzibilna tableta, ki vsebuje estetrol |
| PE20231714A1 (es) | 2015-06-18 | 2023-10-23 | Estetra Sprl | Unidad de dosificacion orodispersable que contiene un componente estetrol |
| UA123098C2 (uk) | 2015-06-18 | 2021-02-17 | Естетра Спрл | Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| KR101996390B1 (ko) * | 2017-04-21 | 2019-07-04 | 이화여자대학교 산학협력단 | 아미노퀴놀린계 화합물을 포함하는 면역 증강용 조성물, 조절 t 세포로의 분화 촉진용 조성물, 및 이를 이용한 방법 |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3440320A (en) | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
| US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
| DE2336433A1 (de) | 1973-07-13 | 1975-04-03 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
| DE2426779A1 (de) | 1974-05-31 | 1975-12-18 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
| DE2336434A1 (de) | 1973-07-13 | 1975-04-17 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
| US4722941A (en) | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
| US4460372A (en) | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
| US4573996A (en) | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
| US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
| US4937238A (en) | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
| US4762717A (en) | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
| US5223261A (en) | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
| US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
| US5130137A (en) | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
| JPH04235171A (ja) | 1990-07-26 | 1992-08-24 | Sumitomo Chem Co Ltd | スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤 |
| US5063507A (en) | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
| US5340586A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
| US5340585A (en) | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US5468736A (en) | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
| NL9301562A (nl) | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| AU2103495A (en) | 1994-08-04 | 1996-03-04 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
| DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| AU8727798A (en) | 1997-06-20 | 1999-01-04 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
| DE19739916C2 (de) | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
| US6214815B1 (en) | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| AU4543200A (en) | 1999-04-16 | 2000-11-02 | Dittgen, Michael | Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
| US7273932B1 (en) | 1999-05-28 | 2007-09-25 | The University Of Cincinnati | Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
| WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| AU5984701A (en) | 2000-05-12 | 2001-11-20 | Univ Oregon Health & Science | Method of treating immune pathologies with low dose estrogen |
| US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| WO2003018026A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
-
2003
- 2003-06-11 ES ES03741634T patent/ES2274252T3/es not_active Expired - Lifetime
- 2003-06-11 CA CA2489271A patent/CA2489271C/en not_active Expired - Lifetime
- 2003-06-11 US US10/517,686 patent/US7923440B2/en active Active
- 2003-06-11 AU AU2003274946A patent/AU2003274946A1/en not_active Abandoned
- 2003-06-11 AT AT03741634T patent/ATE340579T1/de not_active IP Right Cessation
- 2003-06-11 SI SI200330587T patent/SI1511496T1/sl unknown
- 2003-06-11 EP EP03741634A patent/EP1511496B1/en not_active Expired - Lifetime
- 2003-06-11 DE DE60308679T patent/DE60308679T2/de not_active Expired - Lifetime
- 2003-06-11 WO PCT/NL2003/000422 patent/WO2003103684A1/en active IP Right Grant
- 2003-06-11 CN CN03818849XA patent/CN1691947B/zh not_active Expired - Lifetime
- 2003-06-11 DK DK03741634T patent/DK1511496T3/da active
- 2003-06-11 PT PT03741634T patent/PT1511496E/pt unknown
-
2006
- 2006-12-22 CY CY20061101851T patent/CY1105883T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003274946A1 (en) | 2003-12-22 |
| WO2003103684A1 (en) | 2003-12-18 |
| EP1511496A1 (en) | 2005-03-09 |
| ES2274252T3 (es) | 2007-05-16 |
| DK1511496T3 (da) | 2007-02-05 |
| CN1691947A (zh) | 2005-11-02 |
| DE60308679T2 (de) | 2007-08-16 |
| ATE340579T1 (de) | 2006-10-15 |
| CA2489271C (en) | 2011-12-06 |
| SI1511496T1 (sl) | 2007-04-30 |
| EP1511496B1 (en) | 2006-09-27 |
| US7923440B2 (en) | 2011-04-12 |
| PT1511496E (pt) | 2007-01-31 |
| CA2489271A1 (en) | 2003-12-18 |
| CN1691947B (zh) | 2011-11-23 |
| DE60308679D1 (de) | 2006-11-09 |
| US20050261209A1 (en) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105883T1 (el) | Μεθοδος θepαπειας ή προληψης διαταραχων οπου μεσολαβει το ανοσοποιητικο και φαρμακευτικο παρασκευασμα για χρηση σε αυτη | |
| CY1105957T1 (el) | Χρηση οιστρογονων ενωσεων σε συνδυασμο με ενωσεις προγεστογονου (progestogen) σε θepαπεια ορμονικης αντικαταστασης | |
| DE60219954D1 (de) | Neue Indol-2-on Derivate | |
| ECSP045073A (es) | Nuevos derivados de piperazina | |
| NO991700L (no) | Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer | |
| DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
| HUP0301690A2 (hu) | Szinergikus eljárások és készítmények rák kezelésére | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| ATE512976T1 (de) | Hemmer des hepatitis-c-virus | |
| CY1108093T1 (el) | Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη | |
| MX2007011041A (es) | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. | |
| KR950032267A (ko) | 11,21-비스페닐-19-노르프레그난 유도체 | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| BR0211305A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto | |
| ATE358668T1 (de) | Drogen zur behandlung maligner tumoren | |
| DE60014916D1 (de) | Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung | |
| ATE247964T1 (de) | Als inhibitoren der aicarftnützliche verbindungen | |
| ATE180669T1 (de) | Verwendung von pregnanderivaten zur behandlung von tumoren | |
| HUP9904301A2 (hu) | Benzimidazolszármazékok,valamint ezeket tartalmazó gyógyászati készítmények | |
| AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion | |
| ITMI20042475A1 (it) | Uso di derivati tiazolidinonici come agenti terapeutici | |
| MY129575A (en) | Methods, kits and compositions for using pyrrole derivatives againts anxiety | |
| ATE417831T1 (de) | Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel | |
| AP9901559A0 (en) | Tricyclic 3-keto derivatives of 6-0-methylerythromycin. | |
| HUP0303610A2 (hu) | Jóindulatú prosztatatúltengéssel összefüggő húgyhólyag-irritációs tünetek kezelésére alkalmas készítmény |